Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Review Article Volume 3 Issue 1

Role of Safinamide in controlling Pain in Parkinsons Disease

Rajib Dutta1* and Swatilekha Roy Sarkar2#

1MD, Neurology, India

2MDS, Consultant Orthodontist, India

*Corresponding Author: Rajib Dutta, MD, Neurology, India. E-mail:

Received: December 17, 2019; Published: December 23, 2019



   Pain is considered as one of the most important non-motor symptom of Parkinson’s disease (PD) which is frequently overlooked in medical practice. Many patients find it more distressing as compared to the motor symptoms. It is a debilitating symptom with a high prevalence in PD population. It is often underestimated and not treated adequately by clinicians. Quality of life and activities of daily living is severely impaired. The path mechanism of pain in PD is complex and several neurotransmission system is involved which includes glutamergic, serotonergic, noradrenergic, GABAergic, dopaminergic. The fine balance between glutamate and dopamine levels are not maintained in blood and brain in PD patients which somehow explains the neurobiology. Several pharmaceutical agents are present for treatment of pain however the greatest reductions were found with safinamide. Safinamide is now considered as an important adjunct to standard parkinsonian medication for alleviating pain in PD.

Keywords: Safinamide; Pain; Parkinsons Disease; Glutamate; Dopamine



  1. Jankovic J. “Parkinson’s disease: Clinical features and diagnosis”. Journal of Neurology, Neurosurgery, and Psychiatry 79 (2008): 368-376.
  2. Olanow CW and Tatton WG. “Etiology and pathogenesis of Parkinson disease”. Annual Review of Neuroscience 22 (1999): 123-144.
  3. Jellinger KA. “The pathology of Parkinson disease”. Advances in Neurology 86 (2001): 55-72.
  4. Rossi A., et al. “Projection of the prevalence of Parkinson's disease in the coming decades: revisited”. Movement Disorders 33 (2018): 156-159.
  5. Nussbaum RL and Ellis CE. “Alzheimer’s disease and Parkinson’s disease”. The New England Journal of Medicine 348 (2003): 1356-1364.
  6. De Lau LM and Breteler MM. “Epidemiology of Parkinson’s disease”. The Lancet Neurology 5 (2006): 525-535.
  7. Martinez-Martin P., et al. “The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease”. Movement Disorders 26 (2011): 399-406.
  9. Fox SH. “Non-dopaminergic treatments formotor control in Parkinson’s disease”. Drugs 73 (2013): 1405-1415.
  10. Olanow CW., et al. “The scientific and clinical basis for the treatment of Parkinson disease”. Neurology 72 (2009): S1-S136.
  11. Buhmann C., et al. “Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy”. Journal of Neurology 264 (2017): 758-769.
  12. Broen MP., et al. “Prevalence of pain in Parkinson's disease:a systematic review using the modified QUADA Stool”. Movement Disorders 27 (2012): 480-484.
  13. Beiske AG., et al. “Pain in Parkinson's disease: prevalence and characteristics”. Pain 141 (2009): 173-177.
  14. Valkovic P., et al. “Pain in Parkinson’s disease: a cross-sectional study of its prevalence, types, and relationship to depression and quality of life”. Plos one 10 (2015): e0136541.
  15. Ehrt U., et al. “Pain and its relationship to depression in Parkinson disease”. The American Journal of Geriatric Psychiatry 17 (2009): 269- 275.
  16. Pay S and Barasi S. “A study of the connections of nociceptive substantia nigra neurones”. Pain 12.1 (1982):75-89.
  17. Richards CD and Taylor DC. “Electrophysiological evidence for a somatotopic sensory projection to the striatum of the rat”. Neuroscience Letters 30.3 (1982): 235-240.
  18. Burkey AR., et al. “Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception”. The Journal of Neuroscience 19.10 (1999): 4169-4179.
  19. Hagelberg N., et al. “Striatal dopamine D2 receptors in modulation of pain in humans: a review”. European Journal of Pharmacology 500.1-3 (2004): 187-192.
  20. Wasner G and Deuschl G. “Pains in Parkinson’s disease: many syndromes under one umbrella”. Nature Reviews Neurology 8 (2012): 284-294.
  21. Chaudhuri KR., et al. “Non-motor symptoms of Parkinson’s disease: diagnosis and management”. The Lancet Neurology 5 (2006): 235-245.
  22. Chaudhuri KR and Shapira AH. “Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment”. The Lancet Neurology 8.5 (2009): 464-474.
  23. Broetz D., et al. “Radicular and nonradicular back pain in Parkinson’s disease: a controlled study”. Movement Disorders 22 (2007): 853-856.
  24. Truini A., et al. “A mechanismbased classification of pain in multiple sclerosis”. Journal of Neurology (2012).
  25. Martinez-Martin P., et al. “Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease”. Journal of Neurology 259.8 (2012): 1639-1647.
  26. Bernal SA., et al. “PAG mu opioid receptor activation underlies sex differences in morphine antinociception”. Behavioural Brain Research 177.1 (2007): 126-133.
  27. Treede RD., et al. “Neuropathic pain: redefinition and a grading system for clinical and research purposes”. Neurology 70.18 (2008): 1630-1635.
  28. Trail M., et al. “An exploratory study of activity in veterans with Parkinson’s disease”. Journal of Neurology 259.8 (2012): 1686-1693.
  29. Shih JC., et al. “Monoamine oxidase: from genes to behaviour”. Annual Review of Neuroscience 22 (1999): 197-217.
  30. Youdim MB and Weinstock M. “Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation”. Neurotoxicology 25 (2004): 243-250.
  31. Collins GGS., et al. “Multiple forms of human brain mitochondrial mono-amine oxidase”. Nature 225 (1970): 817- 820.
  32. O’Carrol AM., et al. “The deamination of dopamine by human brain monoamine oxidase. Specificity for the two forms in seven brain regions”. Naunyn-Schmiedeberg's Archives of Pharmacology 322 (1983): 198-207.
  33. Yamada M and Yasuhara H. “Clinical pharmacology of MAO inhibitors: safety and future”. Neurotoxicology 25 (2004): 215-221.
  34. Choi DK., et al.  The Journal of Neuroscience 25 (2005): 6594-6600
  35. Nicotra A., et al. “Monoamine oxidase expression during development and aging”. Neurotoxicology 25 (2004): 155-165.
  36. Kumar MJ and Andersen JK. “Perspectives on MAO-B in aging and neurological disease: where do we go from here?” Molecular Neurobiology 30 (2004): 77-89.
  37. Mallajosyula JK., et al. “MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology”. Plos one 3 (2008): e1616.
  38. Mandel S., et al. “Neuroprotective strategies in Parkinson’s disease: an update on progress”. CNS Drugs 17 (2003): 729-762.
  39. Magyar K. “The pharmacology of selegiline”. International Review of Neurobiology 100 (2011): 65-84.
  40. Jenner P and Langston JW. “Explaining ADAGIO—A critical review of the biological basis for the clinical effects”. Movement Disorders 26 (2011): 2316- 2323.
  41. Parkinson Study Group. “Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease”. The New England Journal of Medicine 328 (1993): 176-183.
  42. Olanow CW., et al. “The scientific and clinical basis for the treatment of Parkinson disease”. Neurology 72 (2009): S1-S136.
  43. Fariello RG. “Preclinical evaluation of PNU-151774E as a novel anticonvulsant”. Journal of Pharmacology and Experimental Therapeutics 285 (1998): 397-403.
  44. Chung., et al. Journal of Neuroscience Research 00:00?00 (2015).
  45. Strolin Benedetti MS., et al. “The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats”. Journal of Pharmacy and Pharmacology 46 (1994): 814-819.
  46. Strolin Benedetti MS., et al. “Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073 by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain”. Progress in Brain Research 106 (1995): 123-134.
  47. Dezsi L and Vecsei L. “Safinamide for the treatment of Parkinson’s disease”. Expert Opinion on Investigational Drugs 23 (2014): 729-742.
  48. Fariello RG. “Safi namide”. Neurotherapeutics 4 (2007): 110 -116.
  49. Caccia C., et al. “Safinamide: From molecular targets to a new anti-Parkinson drug”. Neurology 67 (2006): S18-S23.
  50. Carlo Cattaneo., et al. Advances in Therapy 35 (2018): 515 -552. 
  51. Bhattacharya A., et al. “Sodium channel blockers for the treatment of neuropathic pain”. Neurotherapeutics 6 (2009): 663-678.
  52. Rogers M., et al. “The role of sodium channels in neuropathic pain”. Seminars in Cell and Developmental Biology 17 (2006): 571-581.
  53. No authors listed. “Safi namide: FCE 26743, NW 1015, PNU 151774, PNU 151774E”. Drugs R and D 5 (2004): 355-358.
  54. Chazot PL. “Safinamide (Newron Pharmaceuticals)”. Current Opinion in Investigational Drugs 2 (2001): 809-813.
  55. Abdul Rehman Qureshi., et al. Neuroepidemiology 51 (2018): 190-206.
  56. Parkinson J. “An essay on the shaking palsy”. London: Whittingham and Rowland (1817).
  57. Ne`gre-Page`s L., et al. “Chronic pain in Parkinson disease: the cross-sectional French Do PaMiP survey”. Movement Disorders 23 (2008): 1361.
  58. Truini A., et al. “Parkinson disease related pain: a review of recent findings”. Journal of Neurology 260 (2013): 330-334.
  59. Shearer J., et al. “The impact of motor and nonmotor symptoms on health state values in newly diagnosed idiopathic ParkinsoN disease”. Journal of Neurology 259 (2012): 462-468.
  60. Brefel-Courbon C., et al. “Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population”. Pain 141 (2009): 14-18.
  61. Cury RG., et al. “Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms”. European Journal of Pain 20 (2016): 151-165.
  62. Nolano M., et al. “Loss of cutaneous large and small fibers in naı¨ve and L-dopa treated PD patients”. Neurology 89 (2017): 776-784.
  63. Tinazzi M., et al. “Pain and motor complications in Parkinson’s disease”. Journal of Neurology, Neurosurgery, and Psychiatry 77 (2006): 822-825.
  64. Defazio G., et al. “Pain as a nonmotor symptom of Parkinson disease:evidence from a case-control study”. Arch Neurology 65 (2008): 1191-1194.
  65. Chudler EH and Dong WK. “The role of the basal ganglia in nociception and pain”. Pain 60 (1995): 33-38.
  66. Salvati P., et al. “Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound”. Journal of Pharmacology and Experimental Therapeutics 288 (1999): 1151-1159.
  67. Miladinovic T., et al. “Overview of glutamatergic dysregulation in central pathologies”. Biomolecules 5 (2015): 3122-3141.
  68. Bleakman D., et al. “Glutamate receptors and pain”. Seminars in Cell and Developmental Biology 17.5 (2006): 592-604.


Citation: Rajib Dutta and Swatilekha Roy Sarkar. “Role of Safinamide in controlling Pain in Parkinsons Disease". Acta Scientific Microbiology 3.1 (2020): 31-36.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US